StockData
Ironwood Pharmaceuticals Inc logo

Ironwood Pharmaceuticals Inc (IRWD) stock

IRWDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/3062% below fair value
$4.87+0.02 (+0.41%)

Close on Nov 17, 2026Market cap $804.72MP/E 6.3Yield –

Earnings

Ironwood Pharmaceuticals's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Feb 24, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
$133.00M
+8.9% on a year earlier
Non-GAAP net income per share – diluted, Q3 FY2026
$0.36
$0.24 a year earlier
Latest guidance
Raised
Nov 5, 2026 · 3 items

Quarterly results

Revenue and earnings per share from each of Ironwood Pharmaceuticals's earnings releases, newest first

QuarterReportedRevenueYoYEPSAdj. EPSSource
Q4 FY2026ended Dec 31, 2026Feb 24, 2027Expected–––––
Q3 FY2026ended Sep 30, 2026Nov 5, 2026before the open$133.00M+8.9%$0.36$0.36Release
Q2 FY2026ended Jun 30, 2026Aug 6, 2026before the open$113.04M+32.7%$0.31$0.31Release
Q1 FY2026ended Mar 31, 2026May 7, 2026before the open$106.50M+159.1%$0.24$0.24Release
Q4 FY2025ended Dec 31, 2025Feb 25, 2026before the open$47.70M-47.3%-$0.01-$0.01Release
Q3 FY2025ended Sep 30, 2025Nov 10, 2025before the open$122.10M+33.3%$0.23$0.24Release
Q2 FY2025ended Jun 30, 2025Aug 7, 2025before the open$85.20M-9.7%$0.14$0.14Release
Q1 FY2025ended Mar 31, 2025May 7, 2025before the open$41.10M-45.1%-$0.23-$0.14Release
Q4 FY2024ended Dec 31, 2024Feb 27, 2025before the open$90.50M-23.0%$0.02$0.02Release
Q3 FY2024ended Sep 30, 2024Nov 7, 2024before the open$91.60M-19.4%$0.02$0.02Release
Q2 FY2024ended Jun 30, 2024Aug 8, 2024before the open$94.40M-12.1%-$0.01$0.00Release
Q1 FY2024ended Mar 31, 2024May 9, 2024before the open$74.90M-28.0%-$0.03-$0.02Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Ironwood Pharmaceuticals's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
Total RevenueGAAPFY2026$485.00M – $510.00M$450.00M – $475.00MRaisedNov 5, 2026
Total RevenueFY2026$460.00M – $485.00M$450.00M – $475.00MRaisedAug 6, 2026
Adjusted EBITDAnon-GAAPFY2026$350.00M$300.00MRaisedNov 5, 2026
Adjusted EBITDAnon-GAAPFY2026$300.00M$300.00MReaffirmedMay 7, 2026
LINZESS ® U.S. net salesFY2026$1.13B – $1.18B–NewFeb 25, 2026
LINZESS® U.S. net salesFY2026$1.13B – $1.18B–NewJan 2, 2026
U.S. LINZESS Net SalesFY2026$1.20B – $1.25B–RaisedNov 5, 2026
U.S. LINZESS Net SalesFY2026$1.15B – $1.20B$1.13B – $1.18BRaisedAug 6, 2026

Guidance vs results

The last range Ironwood Pharmaceuticals gave before each report, against the figure it then reported. Full years add up the four quarters.

PeriodMetricGuidanceActualResult
FY2025Revenue$290.00M – $310.00M$296.10MΣ4QWithin range

Guidance history

Every forecast Ironwood Pharmaceuticals put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Nov 5, 2026Adjusted EBITDAFY2026$350.00MRaised
Nov 5, 2026U.S. LINZESS Net SalesFY2026$1.20B – $1.25BRaised
Nov 5, 2026Total RevenueFY2026$485.00M – $510.00MRaised
Aug 6, 2026U.S. LINZESS Net SalesFY2026$1.15B – $1.20BRaised
Aug 6, 2026Total RevenueFY2026$460.00M – $485.00MRaised
May 7, 2026Adjusted EBITDAFY2026$300.00MReaffirmed
May 7, 2026U.S. LINZESS Net SalesFY2026$1.13B – $1.18BReaffirmed
May 7, 2026Total RevenueFY2026$450.00M – $475.00MReaffirmed
Feb 25, 2026adjusted EBITDAFY2026$300.00MNew
Feb 25, 2026LINZESS ® U.S. net salesFY2026$1.13B – $1.18BNew
Feb 25, 2026total revenuesFY2026$450.00M – $475.00MNew
Jan 2, 2026Adjusted EBITDAFY2025$135.00MReaffirmed
Jan 2, 2026adjusted EBITDAFY2026$300.00MNew
Jan 2, 2026LINZESS® U.S. net salesFY2026$1.13B – $1.18BNew
Jan 2, 2026LINZESS U.S. net salesFY2025$860.00M – $890.00MReaffirmed
Jan 2, 2026Total revenueFY2025$290.00M – $310.00MReaffirmed
Jan 2, 2026total revenuesFY2026$450.00M – $475.00MNew
Nov 10, 2025Adjusted EBITDAFY2025$135.00MNew
Nov 10, 2025U.S. LINZESS Net SalesFY2025$860.00M – $890.00MNew
Nov 10, 2025Total RevenueFY2025$290.00M – $310.00MNew

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Ironwood Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Results
  3. Results
  4. Results
  5. Results
  6. Results
  7. Results
  8. Results
  9. Results
  10. News
  11. Update
  12. Results
  13. Results
  14. Results
  15. Results

See a number that looks wrong?